These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

62 related articles for article (PubMed ID: 8588450)

  • 1. [Hemodynamics and ergometric performance modified by low dosage oral contraceptives].
    Hartard M; Haber P; Havelec L; Jeschke D
    Zentralbl Gynakol; 1996; 118(1):37-41. PubMed ID: 8588450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Ovarian activity, cycle behavior and tolerance of low dosage oral contraceptives: a comparative study].
    Rossmanith WG; Wirth U; Gasser S; Thun B; Steffens D
    Zentralbl Gynakol; 1997; 119(11):538-44. PubMed ID: 9480608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of two low-dose oral contraceptives on pulsatile gonadotropin secretion.
    Schleussner E; Brueckner T; Brautigam J; Michels W
    Gynecol Endocrinol; 2001 Aug; 15(4):259-64. PubMed ID: 11560098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring performance during the menstrual cycle: a model using oral contraceptives.
    Redman LM; Weatherby RP
    Med Sci Sports Exerc; 2004 Jan; 36(1):130-6. PubMed ID: 14707778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Clinical study of the low dose oral contraceptive novynette].
    Uchikova E; Milchev N
    Akush Ginekol (Sofiia); 2003; 42(4):15-6. PubMed ID: 14577362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Increased fibrinolytic activity during use of oral contraceptives is counteracted by an enhanced factor XI-independent down regulation of fibrinolysis: a randomized cross-over study of two low-dose oral contraceptives.
    Meijers JC; Middeldorp S; Tekelenburg W; van den Ende AE; Tans G; Prins MH; Rosing J; Büller HR; Bouma BN
    Thromb Haemost; 2000 Jul; 84(1):9-14. PubMed ID: 10928462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical study of two monophase oral contraceptives with desogestrel].
    Uchikova E; Milchev N; Markova D; Batashki I; Gŭrova A
    Akush Ginekol (Sofiia); 2007; 46(2):18-21. PubMed ID: 17469446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical evaluation of desogestrel, the first new-generation progestagen, practil 21, on 13,290 women and 74,967 cycles].
    Bilotta P; Favilli S
    Minerva Ginecol; 1987 Dec; 39(12):855-69. PubMed ID: 3329705
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of menstrual cycle phase and oral contraceptive use on intermittent exercise.
    Lynch NJ; Nimmo MA
    Eur J Appl Physiol Occup Physiol; 1998 Nov; 78(6):565-72. PubMed ID: 9840414
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased levels of activated factor VII and decreased plasma protein S activity and circulating thrombomodulin during use of oral contraceptives.
    Quehenberger P; Loner U; Kapiotis S; Handler S; Schneider B; Huber J; Speiser W
    Thromb Haemost; 1996 Nov; 76(5):729-34. PubMed ID: 8950781
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized cross-over study on the effects of levonorgestrel- and desogestrel-containing oral contraceptives on the anticoagulant pathways.
    Tans G; Curvers J; Middeldorp S; Thomassen MC; Meijers JC; Prins MH; Bouma BN; Büller HR; Rosing J
    Thromb Haemost; 2000 Jul; 84(1):15-21. PubMed ID: 10928463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A large observational clinical evaluation of a desogestrel-containing combiphasic oral contraceptive in Germany.
    Vree ML; Schmidt J
    Eur J Contracept Reprod Health Care; 2001 Jun; 6(2):108-14. PubMed ID: 11518448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects on coagulation of levonorgestrel- and desogestrel-containing low dose oral contraceptives: a cross-over study.
    Middeldorp S; Meijers JC; van den Ende AE; van Enk A; Bouma BN; Tans G; Rosing J; Prins MH; Büller HR
    Thromb Haemost; 2000 Jul; 84(1):4-8. PubMed ID: 10928461
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the impact of vaginal and oral administration of combined hormonal contraceptives on hepatic proteins sensitive to estrogen.
    Sitruk-Ware RL; Menard J; Rad M; Burggraaf J; de Kam ML; Tokay BA; Sivin I; Kluft C
    Contraception; 2007 Jun; 75(6):430-7. PubMed ID: 17519148
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycle control, quality of life and acne with two low-dose oral contraceptives containing 20 microg ethinylestradiol.
    Winkler UH; Ferguson H; Mulders JA
    Contraception; 2004 Jun; 69(6):469-76. PubMed ID: 15157791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Mercilon - the optimal oral contraceptive].
    Rachev E; Damianov L; Kolarov G; Novachkov V; Ivanov S
    Akush Ginekol (Sofiia); 2000; 39(3):61-2. PubMed ID: 11188004
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rationale for new oral contraceptive dosing.
    Williams JK
    Int J Fertil Womens Med; 2004; 49(1):30-5. PubMed ID: 15038507
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression.
    Schlaff WD; Lynch AM; Hughes HD; Cedars MI; Smith DL
    Am J Obstet Gynecol; 2004 Apr; 190(4):943-51. PubMed ID: 15118618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood pressure and renal haemodynamic response to salt during the normal menstrual cycle.
    Pechère-Bertschi A; Maillard M; Stalder H; Brunner HR; Burnier M
    Clin Sci (Lond); 2000 Jun; 98(6):697-702. PubMed ID: 10814607
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy, safety and sustainability of treatment continuation and results of an oral contraceptive containing 30 mcg ethinyl estradiol and 2 mg chlormadinone acetate, in long-term usage (up to 45 cycles)--an open-label, prospective, noncontrolled, office-based Phase III study.
    Zahradnik HP; Hanjalic-Beck A
    Contraception; 2008 May; 77(5):337-43. PubMed ID: 18402849
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.